{"pmid":32498581,"title":"Relationship between pregnancy and coronavirus: what we know.","text":["Relationship between pregnancy and coronavirus: what we know.","The identification in China in December 2019 of a new coronavirus (SARS-CoV-2) immediately rekindled the spotlight on a problem also addressed in the past during the epidemics of SARS in 2002-2003 and MERS in 2012: the implications of a possible infection during pregnancy, both for pregnant women and for fetuses and infants. Pregnancy is characterized by some changes involving both the immune system and the pulmonary physiology, exposing the pregnant woman to a greater susceptibility to viral infections and more serious complications. The objective of this review is therefore to analyze the relationship between pregnancy and known coronaviruses, with particular reference to SARS-CoV-2.","J Matern Fetal Neonatal Med","Forestieri, Stefano","Marcialis, Maria Antonietta","Migliore, Lucia","Panisi, Cristina","Fanos, Vassilios","32498581"],"abstract":["The identification in China in December 2019 of a new coronavirus (SARS-CoV-2) immediately rekindled the spotlight on a problem also addressed in the past during the epidemics of SARS in 2002-2003 and MERS in 2012: the implications of a possible infection during pregnancy, both for pregnant women and for fetuses and infants. Pregnancy is characterized by some changes involving both the immune system and the pulmonary physiology, exposing the pregnant woman to a greater susceptibility to viral infections and more serious complications. The objective of this review is therefore to analyze the relationship between pregnancy and known coronaviruses, with particular reference to SARS-CoV-2."],"journal":"J Matern Fetal Neonatal Med","authors":["Forestieri, Stefano","Marcialis, Maria Antonietta","Migliore, Lucia","Panisi, Cristina","Fanos, Vassilios"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498581","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/14767058.2020.1771692","keywords":["covid-19","sars-cov-2","coronavirus","pregnancy"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1668804508664201216,"score":9.490897,"similar":[{"pmid":32322107,"pmcid":"PMC7174004","title":"SARS-CoV-2 Infection in Pregnancy - a Review of the Current Literature and Possible Impact on Maternal and Neonatal Outcome.","text":["SARS-CoV-2 Infection in Pregnancy - a Review of the Current Literature and Possible Impact on Maternal and Neonatal Outcome.","In December 2019, cases of pneumonia of unknown cause first started to appear in Wuhan in China; subsequently, a new coronavirus was soon identified as the cause of the illness, now known as Coronavirus Disease 2019 (COVID-19). Since then, infections have been confirmed worldwide in numerous countries, with the number of cases steadily rising. The aim of the present review is to provide an overview of the new severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) and, in particular, to deduce from it potential risks and complications for pregnant patients. For this purpose, the available literature on cases of infection in pregnancy during the SARS epidemic of 2002/2003, the MERS (Middle East respiratory syndrome) epidemic ongoing since 2012, as well as recent publications on cases infected with SARS-CoV-2 in pregnancy are reviewed and reported. Based on the literature available at the moment, it can be assumed that the clinical course of COVID-19 disease may be complicated by pregnancy which could be associated with a higher mortality rate. It may also be assumed at the moment that transmission from mother to child in utero is unlikely. Breastfeeding is possible once infection has been excluded or the disease declared cured.","Geburtshilfe Frauenheilkd","Stumpfe, Florian M","Titzmann, Adriana","Schneider, Michael O","Stelzl, Patrick","Kehl, Sven","Fasching, Peter A","Beckmann, Matthias W","Ensser, Armin","32322107"],"abstract":["In December 2019, cases of pneumonia of unknown cause first started to appear in Wuhan in China; subsequently, a new coronavirus was soon identified as the cause of the illness, now known as Coronavirus Disease 2019 (COVID-19). Since then, infections have been confirmed worldwide in numerous countries, with the number of cases steadily rising. The aim of the present review is to provide an overview of the new severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) and, in particular, to deduce from it potential risks and complications for pregnant patients. For this purpose, the available literature on cases of infection in pregnancy during the SARS epidemic of 2002/2003, the MERS (Middle East respiratory syndrome) epidemic ongoing since 2012, as well as recent publications on cases infected with SARS-CoV-2 in pregnancy are reviewed and reported. Based on the literature available at the moment, it can be assumed that the clinical course of COVID-19 disease may be complicated by pregnancy which could be associated with a higher mortality rate. It may also be assumed at the moment that transmission from mother to child in utero is unlikely. Breastfeeding is possible once infection has been excluded or the disease declared cured."],"journal":"Geburtshilfe Frauenheilkd","authors":["Stumpfe, Florian M","Titzmann, Adriana","Schneider, Michael O","Stelzl, Patrick","Kehl, Sven","Fasching, Peter A","Beckmann, Matthias W","Ensser, Armin"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32322107","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1055/a-1134-5951","keywords":["2019-ncov","covid-19","sars-cov-2","coronavirus","pregnancy"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission"],"weight":1,"_version_":1666138493773938689,"score":239.873},{"pmid":32232217,"pmcid":"PMC7092922","title":"Risks of Novel Coronavirus Disease (COVID-19) in Pregnancy; a Narrative Review.","text":["Risks of Novel Coronavirus Disease (COVID-19) in Pregnancy; a Narrative Review.","Introduction: The outbreak of the new Coronavirus in China in December 2019 and subsequently in various countries around the world has raised concerns about the possibility of vertical transmission of the virus from mother to fetus. The present study aimed to review published literature in this regard. Methods: In this narrative review, were searched for all articles published in various databases including PubMed, Scopus, Embase, Science Direct, and Web of Science using MeSH-compliant keywords including COVID-19, Pregnancy, Vertical transmission, Coronavirus 2019, SARS-CoV-2 and 2019-nCoV from December 2019 to March 18, 2020 and reviewed them. All type of articles published about COVID-19 and vertical transmission in pregnancy were included. Results: A review of 13 final articles published in this area revealed that COVID-19 can cause fetal distress, miscarriage, respiratory distress and preterm delivery in pregnant women but does not infect newborns. There has been no report of vertical transmission in pregnancy, and it has been found that clinical symptoms of COVID-19 in pregnant women are not different from those of non-pregnant women. Conclusion: Overall, due to lack of appropriate data about the effect of COVID-19 on pregnancy, it is necessary to monitor suspected pregnant women before and after delivery. For confirmed cases both the mother and the newborn child should be followed up comprehensively.","Arch Acad Emerg Med","Panahi, Latif","Amiri, Marzieh","Pouy, Somaye","32232217"],"abstract":["Introduction: The outbreak of the new Coronavirus in China in December 2019 and subsequently in various countries around the world has raised concerns about the possibility of vertical transmission of the virus from mother to fetus. The present study aimed to review published literature in this regard. Methods: In this narrative review, were searched for all articles published in various databases including PubMed, Scopus, Embase, Science Direct, and Web of Science using MeSH-compliant keywords including COVID-19, Pregnancy, Vertical transmission, Coronavirus 2019, SARS-CoV-2 and 2019-nCoV from December 2019 to March 18, 2020 and reviewed them. All type of articles published about COVID-19 and vertical transmission in pregnancy were included. Results: A review of 13 final articles published in this area revealed that COVID-19 can cause fetal distress, miscarriage, respiratory distress and preterm delivery in pregnant women but does not infect newborns. There has been no report of vertical transmission in pregnancy, and it has been found that clinical symptoms of COVID-19 in pregnant women are not different from those of non-pregnant women. Conclusion: Overall, due to lack of appropriate data about the effect of COVID-19 on pregnancy, it is necessary to monitor suspected pregnant women before and after delivery. For confirmed cases both the mother and the newborn child should be followed up comprehensively."],"journal":"Arch Acad Emerg Med","authors":["Panahi, Latif","Amiri, Marzieh","Pouy, Somaye"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232217","source":"PubMed","week":"202014|Mar 30 - Apr 05","keywords":["covid-19","coronavirus","infectious disease transmission","pregnancy","severe acute respiratory syndrome coronavirus 2","vertical"],"locations":["China","Pregnancy"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission"],"weight":1,"_version_":1666138492180103170,"score":220.77444},{"pmid":32328850,"pmcid":"PMC7178925","title":"Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.","text":["Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.","To analyze the susceptibility of SARS-CoV-2 in pregnancy and the drugs that can be used to treat pregnancy with COVID-19, so as to provide evidence for drug selection in clinic. By reviewing the existing literature, this paper analyzes the susceptibility of pregnant women to virus, especially to SARS-CoV-2, from the aspects of anatomical, reproductive endocrine and immune changes during pregnancy and screens effective and fetal-safe treatments from the existing drugs. The anatomical structure of the respiratory system is changed during pregnancy, and the virus transmitted by droplets and aerosols is more easily inhaled by pregnant women and is difficult to remove. Furthermore, the prognosis is worse after infection when compared with non-pregnancy women. And changes in reproductive hormones and immune systems during pregnancy collectively make them more susceptible to certain infections. More importantly, angiotensin-converting enzyme (ACE)-2, the SARS-CoV-2 receptor, has been proven highly increased during pregnancy, which may contribute to the susceptibility to SARS-CoV-2. When it comes to treatment, specific drugs for COVID-19 have not been found at present, and taking old drugs for new use in treating COVID-19 has become an emergency method for the pandemic. Particularly, drugs that show superior maternal and fetal safety are worthy of consideration for pregnant women with COVID-19, such as chloroquine, metformin, statins, lobinavir/ritonavir, glycyrrhizic acid, and nanoparticle-mediated drug delivery (NMDD), etc. Pregnant women are susceptible to COVID-19, and special attention should be paid to the selection of drugs that are both effective for maternal diseases and friendly to the fetus. However, there are still many deficiencies in the study of drug safety during pregnancy, and broad-spectrum, effective and fetal-safe drugs for pregnant women need to be developed so as to cope with more infectious diseases in the future.","Eur J Clin Microbiol Infect Dis","Zhao, Xiaoxuan","Jiang, Yuepeng","Zhao, Yang","Xi, Hongyan","Liu, Chang","Qu, Fan","Feng, Xiaoling","32328850"],"abstract":["To analyze the susceptibility of SARS-CoV-2 in pregnancy and the drugs that can be used to treat pregnancy with COVID-19, so as to provide evidence for drug selection in clinic. By reviewing the existing literature, this paper analyzes the susceptibility of pregnant women to virus, especially to SARS-CoV-2, from the aspects of anatomical, reproductive endocrine and immune changes during pregnancy and screens effective and fetal-safe treatments from the existing drugs. The anatomical structure of the respiratory system is changed during pregnancy, and the virus transmitted by droplets and aerosols is more easily inhaled by pregnant women and is difficult to remove. Furthermore, the prognosis is worse after infection when compared with non-pregnancy women. And changes in reproductive hormones and immune systems during pregnancy collectively make them more susceptible to certain infections. More importantly, angiotensin-converting enzyme (ACE)-2, the SARS-CoV-2 receptor, has been proven highly increased during pregnancy, which may contribute to the susceptibility to SARS-CoV-2. When it comes to treatment, specific drugs for COVID-19 have not been found at present, and taking old drugs for new use in treating COVID-19 has become an emergency method for the pandemic. Particularly, drugs that show superior maternal and fetal safety are worthy of consideration for pregnant women with COVID-19, such as chloroquine, metformin, statins, lobinavir/ritonavir, glycyrrhizic acid, and nanoparticle-mediated drug delivery (NMDD), etc. Pregnant women are susceptible to COVID-19, and special attention should be paid to the selection of drugs that are both effective for maternal diseases and friendly to the fetus. However, there are still many deficiencies in the study of drug safety during pregnancy, and broad-spectrum, effective and fetal-safe drugs for pregnant women need to be developed so as to cope with more infectious diseases in the future."],"journal":"Eur J Clin Microbiol Infect Dis","authors":["Zhao, Xiaoxuan","Jiang, Yuepeng","Zhao, Yang","Xi, Hongyan","Liu, Chang","Qu, Fan","Feng, Xiaoling"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328850","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s10096-020-03897-6","keywords":["antiviral treatment","fetal safety","new coronavirus disease","pregnancy","virus susceptibility"],"e_drugs":["Metformin","Chloroquine","Glycyrrhizic Acid"],"topics":["Treatment"],"weight":1,"_version_":1666138494632722434,"score":211.43263},{"pmid":32199996,"pmcid":"PMC7186548","title":"[SARS-CoV-2 infection during pregnancy. Information and proposal of management care. CNGOF].","text":["[SARS-CoV-2 infection during pregnancy. Information and proposal of management care. CNGOF].","A new coronavirus (SARS-CoV-2) highlighted at the end of 2019 in China is spreading across all continents. Most often at the origin of a mild infectious syndrome, associating mild symptoms (fever, cough, myalgia, headache and possible digestive disorders) to different degrees, SARS-Covid-2 can cause serious pulmonary pathologies and sometimes death. Data on the consequences during pregnancy are limited. The first Chinese data published seem to show that the symptoms in pregnant women are the same as those of the general population. There are no cases of intrauterine maternal-fetal transmission, but cases of newborns infected early suggest that there could be vertical perpartum or neonatal transmission. Induced prematurity and cases of respiratory distress in newborns of infected mothers have been described. Pregnancy is known as a period at higher risk for the consequences of respiratory infections, as for influenza, so it seems important to screen for Covid-19 in the presence of symptoms and to monitor closely pregnant women. In this context of the SARS-Covid-2 epidemic, the societies of gynecology-obstetrics, infectious diseases and neonatalogy have proposed a French protocol for the management of possible and proven cases of SARS-Covid-2 in pregnant women. These proposals may evolve on a daily basis with the advancement of the epidemic and knowledge in pregnant women. Subsequently, an in-depth analysis of cases in pregnant women will be necessary in order to improve knowledge on the subject.","Gynecol Obstet Fertil Senol","Peyronnet, V","Sibiude, J","Deruelle, P","Huissoud, C","Lescure, X","Lucet, J-C","Mandelbrot, L","Nisand, I","Vayssiere, C","Yazpandanah, Y","Luton, D","Picone, O","32199996"],"abstract":["A new coronavirus (SARS-CoV-2) highlighted at the end of 2019 in China is spreading across all continents. Most often at the origin of a mild infectious syndrome, associating mild symptoms (fever, cough, myalgia, headache and possible digestive disorders) to different degrees, SARS-Covid-2 can cause serious pulmonary pathologies and sometimes death. Data on the consequences during pregnancy are limited. The first Chinese data published seem to show that the symptoms in pregnant women are the same as those of the general population. There are no cases of intrauterine maternal-fetal transmission, but cases of newborns infected early suggest that there could be vertical perpartum or neonatal transmission. Induced prematurity and cases of respiratory distress in newborns of infected mothers have been described. Pregnancy is known as a period at higher risk for the consequences of respiratory infections, as for influenza, so it seems important to screen for Covid-19 in the presence of symptoms and to monitor closely pregnant women. In this context of the SARS-Covid-2 epidemic, the societies of gynecology-obstetrics, infectious diseases and neonatalogy have proposed a French protocol for the management of possible and proven cases of SARS-Covid-2 in pregnant women. These proposals may evolve on a daily basis with the advancement of the epidemic and knowledge in pregnant women. Subsequently, an in-depth analysis of cases in pregnant women will be necessary in order to improve knowledge on the subject."],"journal":"Gynecol Obstet Fertil Senol","authors":["Peyronnet, V","Sibiude, J","Deruelle, P","Huissoud, C","Lescure, X","Lucet, J-C","Mandelbrot, L","Nisand, I","Vayssiere, C","Yazpandanah, Y","Luton, D","Picone, O"],"date":"2020-03-23T11:00:00Z","year":2020,"_id":"32199996","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.gofs.2020.03.014","keywords":["covid-19","coronavirus sars-cov-2","covid-19","grossesse","maternal-fetal transmission","newborn","nouveau-ne","pregnancy","transmission materno-foetale"],"locations":["China","myalgia","headache","Chinese","French"],"countries":["China","France"],"countries_codes":["CHN|China","FRA|France"],"topics":["Transmission","Diagnosis"],"weight":1,"_version_":1666138490121748481,"score":203.15594},{"pmid":32217113,"title":"Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.","text":["Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.","The current coronavirus disease 2019 (COVID-19) pneumonia pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading globally at an accelerated rate, with a basic reproduction number (R0) of 2-2.5, indicating that 2-3 persons will be infected from an index patient. A serious public health emergency, it is particularly deadly in vulnerable populations and communities in which healthcare providers are insufficiently prepared to manage the infection. As of March 16, 2020, there are more than 180,000 confirmed cases of COVID-19 worldwide, with more than 7000 related deaths. The SARS-CoV-2 virus has been isolated from asymptomatic individuals, and affected patients continue to be infectious 2 weeks after cessation of symptoms. The substantial morbidity and socioeconomic impact have necessitated drastic measures across all continents, including nationwide lockdowns and border closures. Pregnant women and their fetuses represent a high-risk population during infectious disease outbreaks. To date, the outcomes of 55 pregnant women infected with COVID-19 and 46 neonates have been reported in the literature, with no definite evidence of vertical transmission. Physiological and mechanical changes in pregnancy increase susceptibility to infections in general, particularly when the cardiorespiratory system is affected, and encourage rapid progression to respiratory failure in the gravida. Furthermore, the pregnancy bias toward T-helper 2 (Th2) system dominance, which protects the fetus, leaves the mother vulnerable to viral infections, which are more effectively contained by the Th1 system. These unique challenges mandate an integrated approach to pregnancies affected by SARS-CoV-2. Here we present a review of COVID-19 in pregnancy, bringing together the various factors integral to the understanding of pathophysiology and susceptibility, diagnostic challenges with real-time reverse transcription polymerase chain reaction (RT-PCR) assays, therapeutic controversies, intrauterine transmission, and maternal-fetal complications. We discuss the latest options in antiviral therapy and vaccine development, including the novel use of chloroquine in the management of COVID-19. Fetal surveillance, in view of the predisposition to growth restriction and special considerations during labor and delivery, is addressed. In addition, we focus on keeping frontline obstetric care providers safe while continuing to provide essential services. Our clinical service model is built around the principles of workplace segregation, responsible social distancing, containment of cross-infection to healthcare providers, judicious use of personal protective equipment, and telemedicine. Our aim is to share a framework that can be adopted by tertiary maternity units managing pregnant women in the flux of a pandemic while maintaining the safety of the patient and healthcare provider at its core.","Am J Obstet Gynecol","Dashraath, Pradip","Wong, Jing Lin Jeslyn","Lim, Mei Xian Karen","Lim, Li Min","Li, Sarah","Biswas, Arijit","Choolani, Mahesh","Mattar, Citra","Su, Lin Lin","32217113"],"abstract":["The current coronavirus disease 2019 (COVID-19) pneumonia pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading globally at an accelerated rate, with a basic reproduction number (R0) of 2-2.5, indicating that 2-3 persons will be infected from an index patient. A serious public health emergency, it is particularly deadly in vulnerable populations and communities in which healthcare providers are insufficiently prepared to manage the infection. As of March 16, 2020, there are more than 180,000 confirmed cases of COVID-19 worldwide, with more than 7000 related deaths. The SARS-CoV-2 virus has been isolated from asymptomatic individuals, and affected patients continue to be infectious 2 weeks after cessation of symptoms. The substantial morbidity and socioeconomic impact have necessitated drastic measures across all continents, including nationwide lockdowns and border closures. Pregnant women and their fetuses represent a high-risk population during infectious disease outbreaks. To date, the outcomes of 55 pregnant women infected with COVID-19 and 46 neonates have been reported in the literature, with no definite evidence of vertical transmission. Physiological and mechanical changes in pregnancy increase susceptibility to infections in general, particularly when the cardiorespiratory system is affected, and encourage rapid progression to respiratory failure in the gravida. Furthermore, the pregnancy bias toward T-helper 2 (Th2) system dominance, which protects the fetus, leaves the mother vulnerable to viral infections, which are more effectively contained by the Th1 system. These unique challenges mandate an integrated approach to pregnancies affected by SARS-CoV-2. Here we present a review of COVID-19 in pregnancy, bringing together the various factors integral to the understanding of pathophysiology and susceptibility, diagnostic challenges with real-time reverse transcription polymerase chain reaction (RT-PCR) assays, therapeutic controversies, intrauterine transmission, and maternal-fetal complications. We discuss the latest options in antiviral therapy and vaccine development, including the novel use of chloroquine in the management of COVID-19. Fetal surveillance, in view of the predisposition to growth restriction and special considerations during labor and delivery, is addressed. In addition, we focus on keeping frontline obstetric care providers safe while continuing to provide essential services. Our clinical service model is built around the principles of workplace segregation, responsible social distancing, containment of cross-infection to healthcare providers, judicious use of personal protective equipment, and telemedicine. Our aim is to share a framework that can be adopted by tertiary maternity units managing pregnant women in the flux of a pandemic while maintaining the safety of the patient and healthcare provider at its core."],"journal":"Am J Obstet Gynecol","authors":["Dashraath, Pradip","Wong, Jing Lin Jeslyn","Lim, Mei Xian Karen","Lim, Li Min","Li, Sarah","Biswas, Arijit","Choolani, Mahesh","Mattar, Citra","Su, Lin Lin"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217113","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.ajog.2020.03.021","keywords":["covid-19","mers-cov,morbidity","sars-cov","sars-cov-2","antiviral","baricitinib","chloroquine","coronavirus","fever","mask","mortality","obstetric management","pandemic","pregnancy","remdesivir","respiratory distress syndrome","respiratory failure","sepsis","susceptibility","virus"],"e_drugs":["Chloroquine"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666138492294397954,"score":201.45828}]}